Inst för onkologi-patologi / Dept of Oncology-Pathology: Recent submissions
Now showing items 1-20 of 426
-
Real-world studies on B-cell malignancies
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-11-18)Randomized controlled trials remain the preferred way of evaluating new treatments. However, in studies on malignancies, trial data may not always be sufficient to address the requirements of health care providers and ... -
Biomarkers for CNS metastasis in non-small cell lung cancer (NSCLC)
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-11-18)Non-small cell lung cancer (NSCLC) comprises more than 75% of lung cancer cases and is usually diagnosed in advanced stages. Lung cancer is the leading cause of cancer death among all solid tumours and the second most ... -
Low-dose methadone as add-on to ongoing opioid treatment in cancer-related pain
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-11-17)Background: In complex cancer-related pain in imminently dying patients, even high doses of ordinary opioids may have an insufficient effect. The addition of low-dose methadone to another ongoing opioid has been proposed ... -
Radiation dose and x-ray beam modelling in diagnostic and interventional radiology using Monte Carlo methods
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-11-03)Although medical imaging is essential for the diagnosis and treatment of a wide range of medical conditions, the radiation dose from x-ray examinations is one of the largest contributors to the exposure of the world’s ... -
Improving chemotherapy in advanced urothelial cancer : real-world data studies and prospective clinical trials
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-10-23)Advanced urothelial cancer (UC) is an aggressive disease with high morbidity and mortality. The primary aim of this thesis was to improve chemotherapy with respect to treatment efficacy, safety, and health-related quality ... -
Regulation of cellular degradation pathways by viral oncoproteins and microRNAs
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-10-08)The cellular degradation system actively participates in cell homeostasis. Despite ongoing efforts and much progress in recent years, the underlying mechanisms of these pathways are not entirely understood. This thesis ... -
Immunological alterations, therapies with immune check-point inhibitors and beyond in patients with metastatic melanoma
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-10-07)In the last decade the treatment of metastatic melanoma (MM) has been revolutionized and changed the life of many patients, offering prolonged survival and improved symptom control. These treatment strategies have also ... -
p53 and cancer-associated fibroblasts : implications for cancer therapy and drug resistance
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-10-01)Drug resistance remains as a major problem and a daunting challenge to successful anticancer treatment. Cancer cells are masters of adaptation. Novel drugs that attack cancer in new ways and target key drivers of cancer ... -
MicroRNA and energy metabolism in gastrointestinal tumors
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-09-09)MicroRNAs (miRNAs) contribute to cancer development and drug resistance via cellular biological processes, including metabolic pathways. Energy metabolism plays a significant role to maintain tumor proliferation in ... -
Improving biomarker assessment in breast pathology
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-09-02)The accuracy of prognostic and therapy-predictive biomarker assessment in breast tumours is crucial for management and therapy decision in patients with breast cancer. In this thesis, biomarkers used in clinical practice ... -
Individualized Prostate Cancer Testing : men's views on participation
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-08-19)Prostate cancer (PCa) is the second most common cancer in men in the world and the fourth most common occurring cancer overall. However, because the harms from testing with prostate-specific antigen (PSA) are considered ... -
Intratumoral heterogeneity in glioblastoma: subtype transition and cell-to-cell communication
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-08-06)Glioblastoma is a most aggressive brain tumor with a median overall survival of less than two years. The current treatment is surgery, chemotherapy, and radiotherapy. However, glioblastoma is difficult to treat and recurs ... -
Understanding the response to EGFR targeting therapy in non-small-cell lung cancer using -omics approach
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-07-21)NSCLC is the leading cause of cancer-related death worldwide. EGFR targeted therapy is used to inhibit the progress of NSCLC, but patients inevitably develop resistance to EGFRTKIs. The work presented in this thesis ... -
Prognosis based classification and tumor biology of uterine sarcomas
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-05-15)Uterine stromal sarcomas are a heterogenous group of tumors ranging from low-grade stromal sarcomas with a relatively good survival but high risk of recurrence, to undifferentiated uterine sarcomas with a far worse ... -
Targeted therapy in chronic lymphocytic leukemia
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-04-28)Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 aberration and with refractoriness to ... -
Hitting the right targets : a study of molecular mediators of sensitivity to novel potential targeted therapies in cutaneous malignant melanoma
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-04-24)Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer with a 5-year overall survival (OS) rate of less than 10% among patients diagnosed with disseminated disease. During the past decade the emergence and ... -
Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-04-03)Cancer immunotherapy and especially immune checkpoint blockade therapy has revolutionized cancer treatment in many tumor types including breast cancer (BC). The expression and specific role of Programmed Death-1 (PD-1)/Programmed ... -
Studies of side effects related to adjuvant breast cancer regimens with focus on chemotherapy
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-03-26)Radiotherapy, endocrine therapy, chemotherapy and targeted therapy adjunct to surgery have a critical role in the management of early breast cancer for outcome improvement. Anthracycline containing chemotherapy reduces ... -
Astrocytes in glioblastoma : enhancers of tumor growth, predictors of patient survival and potential therapeutic targets
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-02-18)The tumor microenvironment plays an important role in glioblastoma, the most malignant primary brain tumor in adults. Astrocytes are a major component of the glioblastoma tumor microenvironment; therefore, their influence ... -
Investigation of small-cell lung cancer epidemiology in Sweden and analysis of clinical and tumor specific prognostic biomarkers
(Inst för onkologi-patologi / Dept of Oncology-Pathology, 2020-02-10)Small-cell lung cancer (SCLC) accounts for approximately 13% of all newly diagnosed lung cancer (LC) cases. This disease is correlated with heavy smoking. It is characterized by a rapid doubling time combined with a ...